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Background: Beta-adrenergic antagonists or blockers (BB) are a cornerstone of cardiac
therapy for multiple indications. However, BB are considered relatively contraindicated
in amyloid cardiomyopathy due to poor tolerance. This intolerance is hypothesized
to be due to concomitant neuropathy and significant restrictive cardiomyopathy. This
study analyzes the incidence and characteristics of BB tolerance in patients with
amyloid cardiomyopathy.
Methods: Through a single-center retrospective chart review, patients with amyloid
cardiomyopathy, confirmed by endomyocardial biopsy or technetium-99 pyrophosphate
scan, were identified and clinical data was collected. Statistical methods included
Chi-square test and two sample t-tests.
Results: Of 135 cardiac amyloidosis patients, 27 patients (20.0%) had no BB use, 56
patients (41.5%) were current BB users, and 52 patients (38.5%) were prior BB users.
The most frequent indications for BB use were heart failure, hypertension, coronary
artery disease, and arrhythmia. The most common reason for stopping BB therapy
was hypotension (62.8%) followed by fatigue, bradycardia, and orthostasis. Neurologic
symptoms at the initial BB prescription or most recent evaluation were not significantly
different between current and prior BB users. Their cardiovascular profiles were similar
by ejection fraction, wall thickness, troponin I, and brain natriuretic peptide. There was
no association for BB discontinuation based on amyloid subtype, sex, or race.
Conclusion: The majority of patients with amyloid cardiomyopathy were prescribed
BB, and over half of these patients still tolerated BB therapy. Current and prior BB users
had similar profiles from a cardiovascular and neurologic perspective, with no association
identified to predict BB discontinuation.
Keywords: amyloidosis, heart failure, light chain, pharmacology, transthyretin
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INTRODUCTION

MATERIALS AND METHODS
Ethical Approval

Amyloid cardiomyopathy is increasingly being recognized as an
under-diagnosed cause of heart failure. Through extracellular
deposition of amyloid fibrils, cardiac amyloidosis produces
a non-ischemic, restrictive cardiomyopathy, which initially
manifests as diastolic heart failure and may progress to
systolic dysfunction in later stages. Recent screening studies
have highlighted the need for higher clinical suspicion for
amyloidosis in the setting of heart failure due to a higher
prevalence of amyloid cardiomyopathy in patients with heart
failure than previously thought (1–3). Studies showing higher
prevalence have helped to drive the development of new
treatment modalities for amyloid cardiomyopathy and, more
generally, for various systemic amyloidosis causes (4–7). New
amyloidosis treatments have imparted increased importance in
effectively managing organ-specific amyloid manifestations—
such as amyloid cardiomyopathy—in order to extend
survival (8).
Guideline-recommended medical management of cardiac
amyloidosis sequela—such as heart failure, conduction system
disease, and arrhythmias—can be difficult. Due to systemic
amyloid involvement in peripheral and autonomic nerves,
neuropathy can limit tolerance of neurohormonal medications,
such as beta-adrenergic antagonists or blockers (BBs) (9).
In addition to their utility in preventing adrenergic receptor
downregulation in systolic heart failure, BBs also help prevent
cardiac arrhythmias and are used for atrial fibrillation rate
control (10). Arrhythmia is a frequent complication of amyloid
cardiomyopathy with a prevalence as high as 40% in this
disease population—including a 25% prevalence of atrial
fibrillation—and correlates to poorer hospital outcomes,
increased hospital length-of-stay, and increased hospitalization
cost (11).
Currently, BBs are considered to be relatively contraindicated
in the management of cardiac amyloidosis (3, 9, 12). BBs face
hemodynamic intolerance and bradycardia risk in a heart that
is prone to conduction system disease and may be relying
on compensatory tachycardia for adequate cardiac output (13–
15). BB tolerance has been associated with improved allcause mortality in transthyretin amyloidosis (ATTR) and light
chain amyloidosis (AL) in some studies (16), but not in
others (17).
Novel amyloid treatment can slow disease progression
and enhance survival for cardiac amyloidosis patients (9).
These developments highlight the importance of exploring
patient tolerance to and utility of guideline directed medical
therapy (GDMT) in cardiac amyloidosis. For BB therapy’s
effect on the long-term clinical trajectory of cardiac
amyloid patients to be investigated, these medications
must be hemodynamically tolerated in the short-term.
Through a retrospective observational study, we define the
incidence of BB tolerance and the characteristics that may
be associated with BB tolerance in patients with amyloid
cardiomyopathy seen at our institution between 2008
and 2020.
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The Office of Responsible Research Practices determined this
study (2020E0998) exempt from institutional review board (IRB)
review. In addition, the Ohio State University HIPAA Privacy
Board granted the project a full waiver of HIPAA authorization
by expedited review, according to 45 CFR 164.512.

Participants
Patients with suspected cardiac amyloidosis were identified
based on ICD-9 or ICD-10 codes between 2008 and 2020 at The
Ohio State University Wexner Medical Center (OSU). Inclusion
criteria were diagnosis with wild type transthyretin amyloidosis
(ATTRwt) (E85.82), hereditary or variant transthyretin
amyloidosis (ATTRv) (E85.2), or light chain amyloidosis (AL)
(E85.81) with known cardiac involvement (E85.4); or diagnosis
of heart failure (ICD-9: 428.∗ ; ICD-10:150.∗ ) plus diagnosis of
amyloidosis (ICD-9: 277.3∗ ; ICD-10 E85.∗ ). Exclusion criteria
were clinically unconfirmed disease. Additionally, a single
patient was excluded due to a diagnosis of secondary amyloidosis
(AA). Endomyocardial biopsy-derived pathology specimens
or technetium-99 pyrophosphate scans were used to confirm
disease for AL and ATTR amyloidosis. To increase internal
validity and decrease selection bias, all cardiac amyloidosis
patients seen at OSU during the study timeframe were evaluated
for inclusion and exclusion criteria.
Upon meeting study criteria, patients were stratified to
current, prior, and no BB use groups for analysis. Patients were
grouped in this manner to facilitate comparison of the currentuse and prior-use categories. Patients currently on BB therapy
must be reasonably tolerating therapy, whereas prior BB users
required discontinuation.

Variables
Demographic variables collected were age, sex, and race.
Amyloid type, subtype, and diagnosis date were collected
to characterize disease. BB use was characterized by BB
type, initiation and discontinuation dates, indication,
and reason for discontinuation. Cardiac profiles included
laboratory data (troponin and brain natriuretic peptide)
and imaging data (ejection fraction, stroke volume, and
septal wall thickness via echocardiogram). Neurologic
involvement
was
assessed
by
collecting
reported
neurologic symptoms.
Neurologic and cardiac data were obtained at two separate
timepoints when available. Specific timing of the two data
collection points was based on the category of BB use pattern.
For current BB users, data was collected at or near initial BB
prescription date and at the most recently available datapoint.
For prior BB users, data was collected at or near initial BB
prescription date and at or near BB discontinuation date. For
non-BB users, data was collected at or near initial amyloid
diagnosis and at the most recently available datapoint. These
time points were chosen for their ability to represent clinical
change over the course of BB use and/or disease course. When
possible, data was obtained on the exact relevant date (i.e., vital
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FIGURE 1 | Schematic to identify cardiac amyloidosis patients. Identification of cardiac amyloidosis patients based on ICD codes: Criterion 1, Diagnosis with wild type
Wild-Type Transthyretin Amyloidosis (wtATTR), Light Chain Amyloidosis (AL) or Hereditary Transthyretin Amyloidosis (hATTR), with known cardiac involvement. OR
Criterion 2, Diagnosis of heart failure (ICD-9: 428.* ; ICD-10: I50.* ) plus diagnosis of amyloidosis (ICD-9: 277.3* ; ICD-10 E85.* ). AA, Secondary Amyloidosis; PYP scan,
Technetium-99 Pyrophosphate Scintigraphy.

TABLE 1 | Demographic data by beta blocker use pattern.
Current beta-blocker use

Prior beta-blocker use

No beta-blocker use

Patients (n)

56

52

27

Mean age

71.80 ± 11.28

72.17 ± 10.02

70.73 ± 11.23

Age range (years)

42–96

48–93

44–91

Female (%)

23.20

26.90

25.90

Caucasian (%)

62.50

67.31

85.20

(years ± SD)

Standard deviation (SD).

switched to other BB or only temporarily discontinued. Data
collection was reviewed by two investigators for accuracy.

signs obtained from clinician note for an appointment in which
a BB was prescribed). This proved difficult with some variables.
Specifically, imaging and lab data were frequently gathered from
the available date in nearest proximity to the desired data
collection date.
All patients prescribed a BB were included in the current
or prior category regardless of length of therapy. Indication
data was collected at the point of initial BB prescription,
and not subsequent BB medication changes or additions. BB
discontinuation data was collected only for prior BB users at
the time of final BB discontinuation, and not for BB that were
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Analysis
Continuous variables were reported as mean (standard
deviation) and differences between groups were assessed
via unpaired Student’s T-test. Categorical variables were
reported as percentage (number) and differences between groups
were assessed via chi-square test. Statistical significance was
considered with a P-value <0.05. Stata software was used for all
statistical calculations.
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RESULTS
A total of 624 patients were identified to have suspected
cardiac amyloidosis based on ICD-9 or ICD-10 codes between
2008 and 2020. Of these, 95 records were duplicate and 393
patients were excluded due to lack of confirmed cardiac
involvement via endomyocardial biopsy (for either AL
or ATTR amyloidosis) or technetium-99 pyrophosphate
scan (for ATTR amyloidosis). Additionally, one secondary
amyloidosis (AA) patient was excluded. We identified 135
patients with confirmed amyloid cardiomyopathy meeting
inclusion and exclusion criteria. Of these, 49 had AL
amyloidosis, 45 had ATTRwt amyloidosis, 35 had ATTRm
amyloidosis, and 6 had unspecified ATTR amyloidosis
(Figure 1).
Patients were stratified to current, prior, and no BB use groups
for comparison and analysis (Table 1). In the current BB use

category, there were 56 participants with a mean age of 72 years
(SD = 11.28), 23.2% female, and 62.5% were Caucasian. In
the prior BB use category, there were 52 patients with a mean
age of 72 years (SD = 10.02), 26.9% female, and 67.3% were
Caucasian. In the no BB use category, there were 27 patients
with a mean age of 71 years (SD =11.23), 25.9% female and
85.2% Caucasian.
The most frequent BB indications were heart failure (46.4%
vs. 38.5%), hypertension (28.6% vs. 34.6%), coronary artery
disease (10.6% vs. 4.8%), and arrhythmias (8.9% vs. 5.8%), for
current and prior BB use, respectively (Figure 2). For current
and prior BB use group, there was no statistical difference
in indication for BB initiation (χ 2 = 3.09, p-value = 0.54),
the proportion of patients initially placed on BBs before vs.
after amyloid diagnosis, and the BB type (Table 2). The most
common reasons for stopping BB therapy were hypotension

FIGURE 2 | Beta-blocker indications. Indication for beta-blocker use among
patients receiving current and prior beta-blocker therapy. The current group
includes cardiac amyloid patients who were on beta-blocker therapy at time of
data collection. The prior group includes cardiac amyloid patients who were
previously on beta-blocker therapy but were no longer using beta-blockers at
the time of data collection. The most common reason for beta-blocker therapy
in both groups included heart failure followed by hypertension. CAD, Coronary
Artery Disease, HF, Heart Failure; HTN, Hypertension.

FIGURE 3 | Reasons for beta-blocker discontinuation. Listed are the reasons
for discontinuation of behhta-blocker therapy among cardiac amyloid patients.
The most common reasons for stopping beta-blocker therapy were
hypotension, bradycardia, fatigue, and orthostasis.

TABLE 2 | Beta-blocker (BB) prescription type and timing in relationship to amyloidosis diagnosis.
Current BB use % (N)

Prior BB use % (N)

Test statistic

P-value

8.9 (5)

7.7 (4)

X 2 = 0.0539

0.816

Carvedilol

46.4 (26)

42.3 (22)

X 2 = 0.1854

0.667

Metoprolol

69.6 (39)

80.8 (42)

X 2 = 1.7802

0.182

Prior to amyloid diagnosis

73.2 (41)

77 (40)

X2 = 0.1978

0.657

After amyloid diagnosis

26.8 (15)

23 (12)

BB typea
Atenolol

Timing of initial BB prescription

a only

BB used by at least 5 patients were included.
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TABLE 3 | Comparison of demographic variables compared between patients with current vs prior beta blocker categories.
Variable

Current BB use % (N)

Prior BB use % (N)

Test statistic

Amyloid subtype
AL
ATTRv
ATTRwt
ATTR unspecified

(56)
30 (17)
30 (17)
38 (21)
2 (1)

(52)
34 (18)
25 (13)
31 (16)
10 (5)

X 2 = 3.76

0.288

Sex
Male
Female

(56)
77 (43)
23 (13)

(52)
73 (38)
27 (14)

X 2 = 0.20

0.657

Race
Caucasian
Black
Other

(56)
62 (35)
38 (21)
(0)

(52)
67 (35)
31 (16)
2 (1)

X 2 = 1.53

0.465

P-value

Beta-blocker (BB), Light chain amyloidosis (AL), Variant or hereditary transthyretin amyloidosis (ATTRv), wild-type transthyretin amyloidosis (ATTRwt).

TABLE 4 | Cardiac and neurologic variables by current and prior beta-blocker (BB) use.
Variable

Current BB use
Mean ± SD (N)

Prior BB use
Mean ± SD (N)

Test statistic

P-value

45.36 ± 13.74 (48)

50.10 ± 11.92 (46)

t = 1.78

0.078

43.10 ± 14.39 (41)

43.20 ± 13.65 (47)

t = 0.03

0.972

39.40 ± 14.03 (30)

49.11 ± 25.95 (31)

t = 1.81

0.075

43.86 ± 21.73 (24)

40.25 ± 16.88 (43)

t = −0.76

0.451

1.50 ± 0.43 (38)

1.47 ± 0.42 (40)

t = −0.36

0.721

1.56 ± 0.39 (33)

1.64 ± 0.60 (45)

t = 0.62

0.540

0.18 ± 0.18 (53)

0.24 ± 0.36 (42)

t = 1.22

0.227

0.79 ± 3.22 (48)

0.44 ± 0.95 (49)

t = −0.73

0.468

551.79 ± 469.40 (48)

593.06 ± 755.30 (41)

t = 0.31

0.754

864.27 ± 857.18 (48)

785.71 ± 632.39 (49)

t = −0.51

0.608

52% (29)

52% (27)

X 2 = 0.0002

0.989

Ejection fraction (%)
Initial on BB
Ejection (%)
Most recent on BB
Stroke volume (cm/ml)
Initial on BB
Stroke volume (cm/ml)
Most recent on BB
Septal wall thickness (cm)
Initial on BB
Septal wall thickness (cm)
Most recent on BB
Troponin I (ng/mL)
Initial on BB
Troponin I (ng/mL)
Most recent on BB
Brain natriuretic peptide (pg/mL)
Initial on BB
Brain natriuretic peptide (pg/mL)
Most recent on BB
Neurological symptoms at initial BB prescription % (N)

symptoms at initial BB prescription was not associated with BB
tolerance (Table 4).

(62.8%), bradycardia (11.8%), fatigue (7.8%), and orthostasis
(3.9%) (Figure 3).
Multiple parameters were assessed to determine whether
demographic or disease parameters could account for
discontinuation of BB therapy. No difference was found
between current and prior BB use groups in regard to for
amyloid subtype, sex, and race (Table 3). Current and prior BB
users’ cardiovascular profiles were similar by echocardiogram
parameters including ejection fraction (45% vs. 50%) and wall
thickness (1.50 vs. 1.47 cm) and by cardiac biomarkers including
troponin I (0.175 vs. 0.244 ng/mL), and brain natriuretic
peptide (552 vs. 593 pg/mL). The presence of neurological

Frontiers in Cardiovascular Medicine | www.frontiersin.org

DISCUSSION
In this study of 135 patients at a US tertiary referral center with
confirmed amyloid cardiomyopathy, the majority of patients
(80%) were prescribed BBs with 41.5% of study patients as
current BB users. Our study reports a much higher baseline
prescription rate of BB than previously described, which may
reflect differences in US practice patterns as well as differences
in subtypes of amyloidosis, including ATTRv. In a retrospective
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FIGURE 4 | Summary Figure. Beta-blocker use and tolerance were analyzed in a cohort of patients with confirmed amyloid cardiomyopathy in a large amyloidosis
referral center in the United States. The most common indications for beta blocker (BB) therapy in our cohort included heart failure, hypertension, arrhythmia, and
coronary artery disease. Most patients in our study cohort were prescribed a beta blocker (BB). Of these, over half of them were tolerating the therapy enough to
remain on the medication. Between patient groups tolerating (Current BB Use) and not tolerating (Prior BB Use) BB therapy, no significant differences in cardiac
profiles, neurologic symptom incidence, amyloid type, or demographic data exist. The most common reasons for BB discontinuation include hypotension,
bradycardia, fatigue, and orthostasis.

symptom incidence, amyloid type (AL or ATTR), BB type, or
demographic data were found in our study. One study did
find increased BB intolerance in patients with more advanced
AL disease with higher NYHA class and Mayo stage (19).
Nevertheless, few analyses have found significant association in
BB intolerance—in part because the numbers are small.
Although our study did not find any significant differences
between groups tolerant and intolerant to BB therapy, it does
build on a prevalent tolerance of BB therapy in amyloid
cardiomyopathy seen in the above studies. The number of
patients both prescribed and tolerating BB therapy in our
study demonstrates the clinical complexity formed by competing
considerations of GDMT heart failure strategies and the specific
conduction system and neurohormonal concerns in the amyloid
population. Determining whether the long-term efficacy of BB
in amyloid cardiomyopathy is equivalent to the GDMT benefit
in other forms of heart failure remains unknown and is an
imperative future study.
Limitations to this study include the retrospective nature
at a single institution, which introduces the potential for
measurement bias in relation to clinical care data. Though
appropriate steps were taken to limit this, some data points
were either missing or unable to be collected at the exact
appropriate time. Missing laboratory data prevented reporting of
clinical staging data, which may have proved useful to investigate
relationships between disease severity and BB tolerance. Further,

study of Italian patients with ATTR cardiac amyloidosis, only
57% of patients were prescribed BB and 33% of patients
continued on BB therapy (18). A Spanish study of 128 ATTR
cardiomyopathy patients found 50.8% on BB therapy with an
only 25% discontinuation rate (16). A Greek study of 53 patients
with AL amyloid cardiomyopathy on BB therapy found that 47%
discontinued therapy. (19) Intentional prescription of BB was
able to increase patients on BB therapy from 61 to 87% without
an increase in adverse events in a recent Italian study (20). The
prevalence of BB use at final data collection point in our study
correlates with other real-world, non-trial analyses of BB use
among amyloid cardiomyopathy patients (21).
Investigation into factors associated with BB tolerance among
amyloid cardiomyopathy patients has been limited (22). In our
study, heart failure and hypertension comprised the majority
of documented reasons for BB initiation. An Italian study of
642 patients with cardiac amyloidosis found BB prescription was
driven primarily by atrial fibrillation or ventricular arrhythmias
(18). This striking difference in initiation reasons may reflect
higher prevalence of underlying hypertension in the US
population. Left ventricular ejection fraction was also higher
overall in the Italian study. Consistent with other clinical
observations, hypotension was the most common reason for BB
discontinuation in this study.
Between patients who were discontinued or continued on BB
therapy, no significant differences in cardiac profiles, neurologic
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the impact of BB on outcomes could not be appropriately judged
in this analysis. Although our study is relatively large in this
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be predictive of BB tolerance, ideal BB regimens for patients
tolerating therapy, and the effects of BB therapy on cardiac
disease progression.
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